Sugi Predict

Sugi Predict / Compounds / Phenylthiourea

Phenylthiourea

Phenylthiourea

SCHEMBL1387784

NC(S)=Nc1ccccc1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR3E A5X5Y0 2/20 0.64
▸ HTR3B O95264 2/20 0.64
▸ HTR3A P46098 2/20 0.64
▸ HTR3D Q70Z44 2/20 0.64
▸ HTR3C Q8WXA8 2/20 0.64
▸ SLC22A2 O15244 2/20 0.64
▸ SLC22A1 O15245 1/20 0.64
▸ SLC22A3 O75751 1/20 0.64
▸ PLAU P00749 1/20 0.64
▸ NOS1 P29475 8/20 0.61
▸ NOS3 P29474 5/20 0.61
▸ KMT2A Q03164 2/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ LMNA P02545 2/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ NFKB1 P19838 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ BLM P54132 1/20 0.54
▸ CYP2D6 P10635 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylthiourea SCHEMBL7030440 1.00 HTR3E (0.64) HTR3EHTR3BHTR3AHTR3DHTR3C
Phenylthiourea SCHEMBL4752640 0.97 HTR3E (0.61) HTR3EHTR3BHTR3AHTR3DHTR3C
Phenylthiourea SCHEMBL1286888 0.97 HTR3E (0.61) HTR3EHTR3BHTR3AHTR3DHTR3C
Phenylthiourea SCHEMBL28703542 0.85 NOS1 (0.52) HTR3EHTR3BHTR3AHTR3DHTR3C
Phenylguanidine SCHEMBL467577 0.78 SLC22A2 (1.00) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL7448212 0.76 NOS1 (1.00) HTR3EHTR3BHTR3AHTR3DHTR3C
Phenylguanidine SCHEMBL11092912 0.76 SLC22A2 (0.94) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3785375 0.76 NOS1 (1.00) HTR3EHTR3BHTR3AHTR3DHTR3C
Phenylguanidine SCHEMBL4739913 0.76 SLC22A2 (0.94) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL6273560 0.76 NOS1 (1.00) HTR3EHTR3BHTR3AHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109134326-A A kind of synthetic method of S- arylthio sulfone compound 嘉兴学院 2019-01-04 — — CN claimed
US-6570015-B2 Reacting alpha-keto ester with an isothiourea UBE INDUSTRIES, LTD. (JP) 2003-05-27 — — US claimed
US-20030055252-A1 Process for producing 2-substituted thiopyrimidine-4-carboxylate UBE INDUSTRIES, LTD. (JP) 2003-03-20 — — US claimed
JP-H09504278-A — — 1997-04-28 — — JP claimed
EP-0723438-A1 SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1996-07-31 — — EP claimed
WO-1995009619-A2 SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1995-04-13 — — WO claimed
CN-116970697-A Use of SLC26A2 mutation in diagnosis of multiple epiphyseal dysplasia 北京市创伤骨科研究所 2023-10-31 — — CN disclosed
CN-113299866-B Film layer and preparation method thereof, and light-emitting device and preparation method thereof 合肥福纳科技有限公司 2023-04-07 — — CN disclosed
CN-114957438-A Human Abeta 1-42 antigenic determinant polypeptide for detecting Alzheimer disease and preparation method thereof 亿彤科技发展(福建)有限公司 2022-08-30 — — CN disclosed
CN-114920851-A Abeta 1-42 antigen and application thereof in detecting Abeta 1-42 concentration in Alzheimer patient 亿彤科技发展(福建)有限公司 2022-08-19 — — CN disclosed
CN-109134326-B Synthetic method of S-aryl thiosulfone compound 嘉兴学院 2020-08-28 — — CN disclosed
CN-109134326-B Synthetic method of S-aryl thiosulfone compound 嘉兴学院 2020-08-28 — — CN disclosed
CN-109134326-A A kind of synthetic method of S- arylthio sulfone compound 嘉兴学院 2019-01-04 — — CN disclosed
EP-0256985-A2 Substituted thio ureas, isothio ureas and carbodiimides CIBA-GEIGY AG (CH) 1988-02-24 — — EP disclosed
US-4647557-A Novel heterocyclic derivatives bearing an amino radical, processes for their production and the pharmaceutical compositions containing them MOINET GERARD (FR) 1987-03-03 — — US disclosed
US-4021571-A ANTHELMINTICS BAYER AKTIENGESELLSCHAFT (DT) 1977-05-03 — — US disclosed
US-4021571-A ANTHELMINTICS BAYER AKTIENGESELLSCHAFT (DT) 1977-05-03 — — US disclosed
US-4005123-A ANTHELMINTIC AGENTS BAYER AKTIENGESELLSCHAFT (DT) 1977-01-25 — — US disclosed
US-4005123-A ANTHELMINTIC AGENTS BAYER AKTIENGESELLSCHAFT (DT) 1977-01-25 — — US disclosed
US-3931216-A Process for the manufacture of 2-arylamino-2-imidazoline derivatives and their salts BOEHRINGER INGELHEIM GMBH (DT) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055252-A1 Process for producing 2-substituted thiopyrimidine-4-carboxylate DHFR, TYMS, DPYD HTR3E 2887/4885HTR3B 2799/4885HTR3A 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.